Through these observational data, the augmentation of NK-cell activity with lenalidomide and the simultaneous exploitation of tafasitamab’s FcγR modifications to further enhance ADCC, ADCP and NK-cell localization to tumor cells via CD19 binding (Figure 1) represents a rational and novel combination strategy worth being explored in DLBCL. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.